Evidence map›Paper›PMID 40179881›Full record

ArticleCell2025

Engineering sonogenetic EchoBack-CAR T cells.

Longwei Liu, Peixiang He, Yuxuan Wang, Fengyi Ma, Dulei Li, Zhiliang Bai, Yunjia Qu, Linshan Zhu, Chi Woo Yoon, Xi Yu and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  14. Article
  15. Article
  16. Review
  17. Oncolytic Probiotics with Molecular Pili for Solid Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  18. Article
  19. Mechanomedicine.Nature reviews bioengineering · 2026
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Longwei LiuAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA. Electronic address: longweil@usc.edu.
Peixiang HeAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA; Department of Bioengineering, Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Yuxuan WangAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Fengyi MaAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Dulei LiAcoustic Cell Therapy, Inc., San Diego, CA 92130, USA.
Zhiliang BaiDepartment of Biomedical Engineering, Yale University, New Haven, CT 06520, USA.
Yunjia QuAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA; Department of Bioengineering, Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Linshan ZhuAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Chi Woo YoonAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Xi YuAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Yixuan HuangAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Zhengyu LiangDepartment of Bioengineering, Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Yiming ZhangAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Kunshu LiuAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Tianze GuoAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Yushun ZengAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Qifa ZhouAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
H Kay ChungLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Cell Biology & Physiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Rong FanDepartment of Biomedical Engineering, Yale University, New Haven, CT 06520, USA.
Yingxiao WangAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA; Department of Bioengineering, Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: ywang283@usc.edu.

Funding

Role of Spatiotemporal Epigenetic Dynamics in Regulating Endothelial Gene Expressions under FlowsR01HL121365 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHIEN, SHU, WANG, YINGXIAO · 2014 to 2025
$7.5M
Ultrasensitive kinase biosensors for multiplex imaging of coordinated spatiotemporal signaling in cancer-immune interactionsR01CA262815 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Yingxiao Wang, Jin Zhang · 2022 to 2026
$3.3M
Single Cell Tracking of 3D Epigenetic Landscape Evolution During Embryonic DevelopmentR01HD107206 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Yingxiao Wang, Sheng Zhong · 2022 to 2026
$3.2M
Acoustothermogenetics for Cell EngineeringR35GM140929 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WANG, YINGXIAO · 2021 to 2025
$2.9M
New tools for quantitative non-invasive recording of biochemical signalsR01CA279813 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer Prescher, Nathan Christopher Shaner · 2024 to 2026
$2.0M
Ultrasound-controlled remote activation of CAR T cells for localized tumor immunotherapyR01EB029122 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI WANG, YINGXIAO · 2020 to 2023
$1.7M
Next-generation T cell therapy: SMARTER T cells for enhanced and durable anti-tumor immunityK01EB034321 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hokyung Kay Chung · 2023 to 2026
$639k
Development of single fluorophore biosensors for multiplex imaging of CAR T SignalingK01EB035649 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Longwei Liu · 2024 to 2026
$455k
NCI NIH HHS R01 CA262815NCI NIH HHS R01 CA279813NHLBI NIH HHS R01 HL121365NIBIB NIH HHS K01 EB034321NIBIB NIH HHS K01 EB035649NIBIB NIH HHS R01 EB029122NICHD NIH HHS R01 HD107206NIGMS NIH HHS R35 GM140929
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapy for solid tumors encounters challenges such as on-target off-tumor toxicity, exhaustion, and limited T cell persistence. Here, we engineer sonogenetic EchoBack-CAR T cells using an ultrasensitive heat-shock promoter screened from a library and integrated with a positive feedback loop from CAR signaling, enabling long-lasting CAR expression upon focused-ultrasound (FUS) stimulation. EchoBack-hGD2CAR T cells, targeting disialoganglioside GD2, exhibited potent cytotoxicity and persistence in 3D glioblastoma (GBM) models. In mice, EchoBack-hGD2CAR T cells suppressed GBM without off-tumor toxicity and outperformed their constitutive counterparts. Single-cell RNA sequencing revealed enhanced cytotoxicity and reduced exhaustion in EchoBack-CAR T cells compared with the standard CAR T cells. This EchoBack design was further adapted to target prostate-specific membrane antigen (EchoBack-PSMACAR) for prostate cancer treatment, demonstrating long-lasting tumor suppression with minimal off-tumor toxicity. Thus, the sonogenetic EchoBack-CAR T cells can serve as a versatile, efficient, and safe strategy for solid tumor treatment.

Indexed as

GlioblastomaImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorHumansMaleMiceProstatic NeoplasmsReceptors, Chimeric AntigenCAR Tfeedback engineeringimmunotherapyinducible gene expressionpromoter library screeningsolid tumorsonogeneticsspatiotemporal CAR regulationultrasound controled CAR-T

Identifiers

PMID40179881
PMCPMC12085297

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.